[1]
|
T. Bottiglieri, P. Godfrey, T Flynn, et al., “Cerebrospinal Fluid S-adenosylmethionine in Depression and Dementia: Effect of Treatment with Parenteral and Oral S-adenosyl- Methionine,” Journal of Neurology, Neurosurgery and Psychiatry, Vol. 53, 1990, pp. 1096-1098.
doi:10.1136/jnnp.53.12.1096
|
[2]
|
M Carney, “Serum Folate Values in 423 Psychiatric Patients,” British Medical Journal, Vol. 4, No. 5578, 1967, pp. 512-516. doi:10.1136/bmj.4.5578.512
|
[3]
|
E. Reynolds, J. Preece, J. Bailey, et al., “A Folate Deficiency in Depressive Illness,” British Journal of Psychiatry, Vol. 117, No. 538, 1970, pp. 287-292.
|
[4]
|
P. S. Godfrey, B. K. Toone, M. W. Carney, et al. “Enhancement of Recovery from Psychiatric Illness by Methylfolate,” Lancet, Vol. 336, No. 8720, 1990, pp. 953- 954.
|
[5]
|
T. Bottiglieri, E. Reynolds, B. K. Toone, et al., “CSF S- adenoslymethionine in Neurospcyhatirc Disorders,” Lancet, Vol. 338, No. 8759, 1991, p. 121.
|
[6]
|
L. Morrison, D. Smith and S. Kish. “Brain S-adenosylme- thionine Levels Are Severely Decreased in Alzheimer’s Disease,” Journal of Neurochemistry, Vol. 67, No. 3, 1996, pp. 1328-1331.
doi:10.1046/j.1471-4159.1996.67031328.x
|
[7]
|
T. Bottiglieri, K. Hyland and E. Reynolds. “The Clinical Potential of Ademetionine (S-adenosylmethionine) in Neurological Disorders,” Drugs, Vol. 48, No. 2, 1994, pp. 137-155.
|
[8]
|
E. Reynolds, M. Camey, B. Toone, et al., “Transmethylation and Neuropsychiatry,” In: J. M. Mato, Ed., Proceedings of the 1st Conference on Biochemical, Pharmacological and Clinical Aspects of Transmethylation, Jarpyo, Madrid, 1986, pp. 93-102.
|
[9]
|
E. Reynolds, P. Godfrey, T. Bottiglieri, et al., “S-adeno- sylmethionine and Alzheimer’s Disease,” Neurology, Vol. 39, Suppl. 1, 1989, p. 397.
|
[10]
|
B. Cohen, A. Satlin and G. Zubenko. “S-adenosylmethionine in the Treatment of Alzheimer’s Dementia,” Journal of Clinical Psychopharmacology, Vol. 8, 1988, pp. 43-47.
|
[11]
|
M. Cimino, G. Vantini, S. Algeri, et al., “Age-Related Modification of Dopaminergic and Beta-Adrenergic Receptor System: Restoration to Normal Activity by Modifying Membrane Fluidity with S-adenosylmethionine,” Life Sciences, Vol. 34, No. 21, 1984, pp. 2029-2039. doi:10.1016/0024-3205(84)90367-9
|
[12]
|
T. Shea and A. Chan, “S-adenosyl Methionine: A Natural Therapeutic Agent Effective against Multiple Hallmarks and Risk Factors Associated with Alzheimer’s Disease,” Journal of Alzheimers Disease, Vol. 13, No. 1, 2008, pp. 67-70.
|
[13]
|
B. Kagan, D. Sultzer, N. Rosenlicht and R. Gerner, “Oral S-adenosylmethionine in Depression: A Randomized, Double-Blind, Placebo-Controlled Trial,” American Journal of Psychiatry, Vol. 147, No. 5, 1990; pp. 591- 595.
|
[14]
|
“Diagnostic and Statistical Manual of Mental Disorders,” 4th Edition, American Psychiatric Association Press, Washington D.C., 1994.
|
[15]
|
W. Rosen, R. Mohs and K. Davis. “A New Rating Scale for Alzheimer’s Disease,” American Journal of Psychiatry, Vol. 141, No. 11, 1984, pp. 1356-1364.
|
[16]
|
M. Folstein, S. Folstein and P. McHugh, “Mini-Mental State: A Practical Method for Grading the Cognitive State of Patients for the Clinician,” Journal of Psychiatric Research, Vol. 12, No. 3, 1975, pp. 189-198.
doi:10.1016/0022-3956(75)90026-6
|
[17]
|
B. Reisberg, “Alzheimer’s Disease,” In: E. Sadavoy, L. Lazarus, L. Jarvik, and G. Grossberg , Eds., Comprehensive Review of Geriatric Psychiatry II, American Psychiatric Press, Inc., Washington D.C., 1996, p. 430.
|
[18]
|
B. Reisberg, J. Borenstein, S. Salob, et al., “Behavioral Symptoms in Alzheimer’S Disease: Phenomenology and Treatment,” Journal of Clinical Psychiatry, Vol. 48, Suppl. 5, 1987, pp. 9-15.
|
[19]
|
M. Hamilton, “A Rating Scale for Depression,” Journal of Neurology, Neurosurgery and Psychiatry, Vol. 23, No. 1, pp. 56-62. doi:10.1136/jnnp.23.1.56
|
[20]
|
G. Blessed, B. E. Tomlinson and M. Roth, “The Association between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects,” British Journal of Psychiatry, Vol. 114, No. 512, 1968, pp. 797-811. doi:10.1192/bjp.114.512.797
|
[21]
|
M. P. Lawton and E. M. Brody, “Assessment of Older People: Self-maintaining and Instrumental Activities of Daily Living,” Gerontologist, Vol. 9, No. 3, 1969, pp. 179-186.
|
[22]
|
E. Peskind, “Pharmacologic Approaches to Cognitive Deficits in Alzheimer’s Disease,” Journal of Clinical Psychiatry, Vol. 59, Suppl. 9, 1998, pp. 22-27.
|
[23]
|
G. Small, P. Rabins, P. Barry, et al., “Diagnosis and Treatment of Alzheimer Disease and Related Disorders,” Journal of the American Medical Association, Vol. 278, No. 16, 1997, pp. 1363-1371.
doi:10.1001/jama.278.16.1363
|
[24]
|
S. Scarpa, A. Fuso, et al., “Presenilin 1 Gene Silencing by S-adenosylmethionine: A Treatment For Alzheimer’s Disease?” FEBS Letters, Vol. 541, 2003, pp. 145-148.
doi:10.1016/S0014-5793(03)00277-1
|